GC Biopharma gets a company license for the building of a plasma fractionation plant and technological innovation transfer in Indonesia

YONGIN, South Korea, June 1, 2023 /PRNewswire/ — GC Biopharma, a South Korean biopharmaceutical firm, announced on Jun. 1st that it has efficiently obtained closing acceptance from the Indonesian Ministry of Health for the construction of a plasma fractionation plant and technologies transfer.

(PRNewsfoto/GC Biopharma)

Earlier in Jan., the business was successfully chosen by the Indonesian authorities as the chosen bidder for the license of plasma fractionation plant construction and engineering transfer enterprise. Following some thorough consultation and fine-tuning discussions, the corporation has gained an official acceptance detect for the small business.

GC Biopharma is the only corporation around the globe that has successfully finished the turnkey venture of a plasma fractionation plant in an overseas market. Given that its first export of a plasma fractionation plant to Thailand, GC Biopharma has been accumulating knowledge and know-how in overseas plant design by profitable projects in several nations around the world which include China and Canada.

The plant job is the Indonesian government’s roadmap to noticing a stable and self-sufficient source of plasma derivatives derived from the plasma of Indonesian men and women. Presently, the county depends 100 % on imported plasma derivatives.

“The venture will be but a further chance for us to be internationally recognized for our outstanding plasma fractionation technological know-how and the firm’s 50 %-century legacy”, stated GC Biopharma and added that the distinct agreement sizing and other particulars will be introduced when the official agreement is signed. This task holds significance in that it is a final result of consistent endeavours and collaboration amongst the Korean government and the personal sector in the subject of biopharmaceuticals, main to profitable bidding from a international governing administration.

GC Biopharma initial began generating albumin in the 1970s and because then on, it has been developing several plasma derivatives. Now, the organization materials 12 items to 32 nations all over the world from its Ochang plant. Proven in 2009, the Ochang plant is Asia’s most significant plasma fractionation plant.

About GC Biopharma

GC Biopharma (previously identified as Inexperienced Cross Corporation) is a biopharmaceutical firm that provides lifetime-conserving and lifestyle-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is a person of the major plasma protein and vaccine item producers globally and has been dedicated to good quality health care options for more than fifty percent a century.

This push launch may perhaps comprise biopharmaceuticals in ahead-seeking statements, which convey the present beliefs and anticipations of GC Biopharma’s administration. Such statements do not stand for any promise by GC Biopharma or its administration of potential general performance and entail regarded and unknown hazards, uncertainties and other elements. GC Biopharma undertakes no obligation to update or revise any ahead-wanting assertion contained in this press launch or any other ahead-searching statements it might make, apart from as essential by law or inventory trade rule.

GC Biopharma Contacts (Media)

Seunghyun Baek
[email protected]

Sohee Kim
[email protected]

Yelin Jun
[email protected]





View primary material to download multimedia:https://www.prnewswire.com/news-releases/gc-biopharma-receives-a-organization-license-for-the-development-of-a-plasma-fractionation-plant-and-technology-transfer-in-indonesia-301840768.html

Supply GC Biopharma